Mario Negri Institute

Name

Mario Negri Institute

Legal name

Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Website

https://marionegri.it

Company type

Private

Founded year

1963

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Clinical Research Support (CRC/CTA) (EDAOAJAO), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

Keywords

• Biomedical research
• Pharmacological research
• Clinical trials
• Rare disease research
• Drug information services

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Donations and Charitable Contributions: The institute is funded primarily through donations from individuals, organizations, and charitable contributions. The website encourages donations through various methods including bank transfer, postal payments, and online donation options.
2. Testamentary Bequests: The institute accepts testamentary bequests where individuals can leave money, real estate, stocks, bonds, investment funds, severance pay (TFR), or life insurance policies to support biomedical research.
3. Public Funding (PNRR): The institute receives funding through Italy's National Recovery and Resilience Plan (Piano Nazionale di Ripresa e Resilienza) for specific research projects and healthcare system reform studies.
4. Training Program Fees: Revenue from educational programs including Clinical Monitor courses (22 months), PhD programs in Clinical and Experimental Pharmacology, and specialized training courses.
5. 5x1000 Tax Designation: Italian taxpayers can designate 5x1000 of their tax return to the institute, providing a mechanism for ongoing public financial support.
6. Sponsored Research: The institute conducts commissioned research projects funded by foundations, government bodies, and organizations. Example: Fondazione Cav. Lav. Carlo Pesenti funded the ORIGIN COVID-19 genetic study.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels9 records

Core offering

Mario Negri Institute is a non-profit pharmacological research institute (IRCCS) that conducts biomedical research spanning oncology, neurology, kidney disease, rare diseases, and COVID-19 genetics. It delivers drug information services to healthcare professionals and citizens through dedicated hotlines and the Intercheck web/mobile application, operates the Clinical Research Center Aldo e Cele Daccò for rare diseases, and runs a 22-month Clinical Monitor training program and PhD programs in clinical and experimental pharmacology.

Product overview

Mario Negri Institute (Istituto di Ricerche Farmacologiche Mario Negri IRCCS) is a non-profit pharmacological research institute operating in biomedical research. The organization offers a portfolio of healthcare information services including the Intercheck web/mobile application for elderly drug prescription support, disease-specific information services (Mamma e Bambino, Rare Diseases, Kidney Diseases, Elderly and Drugs), and operates the Clinical Research Center Aldo e Cele Daccò for rare diseases. Educational offerings include a 22-month Clinical Monitor training course. Research activities focus on oncology (including ovarian, pancreatic, lung cancers, mesothelioma, thymoma), COVID-19 genetics (ORIGIN project), stroke, and drug development. The Institute publishes the quarterly Negri News magazine and monthly newsletter, and supports national oncology guidelines development.

Differentiator

Problem solved

Functional benefit

Brands

• Intercheck: Web application for healthcare professionals to support proper drug prescription in the elderly
• Progetto ORIGIN
• Centro Clinico Aldo e Cele Daccò

Products and services

• Intercheck Web/Mobile App Web application and mobile app (Android/iOS) for healthcare professionals to support proper drug prescription in the elderly, monitoring drug interactions and avoiding inappropriate prescriptions.
• Mamma e Bambino Service Information service for pregnant and nursing mothers on the appropriate use of medicines during pregnancy and breastfeeding, with email consultation and forum access.
• Rare Diseases Service Information service for healthcare professionals and patients on therapeutic plans and rare diseases, including biochemical and genetic diagnostics.
• Kidney Diseases Service Information service for healthcare professionals and patients on kidney diseases and transplants, with email consultation and forum access.
• Elderly and Drugs Service (Anziani e Farmaci) Information service for healthcare professionals and the public on correct drug use, side effects, and interactions in elderly patients, with phone and email support.
• Clinical Monitor Course A 22-month professional training program for clinical trial monitoring combining theoretical lessons, supervised monitoring activities, autonomous monitoring, group research, seminars, and monographic courses, awarding Clinical Monitor certification.
• Oncology Research Programs Comprehensive cancer research covering ovarian carcinoma chemotherapy resistance, pancreatic cancer microenvironment, lung cancer organoid models, mesothelioma biomarkers, thymoma database, and the TRABEPIO myxoid liposarcoma clinical study.
• National Oncology Guidelines Co-authored 27 national oncology guidelines with the Italian National Health System and Medical-Scientific Societies, officially recognized by the Ministry of Health as essential tools for physicians nationwide.
• Stroke Research Program Long-standing research program on stroke causes, symptoms, treatments, and biomarker identification conducted through national and international collaboration networks in both preclinical and clinical hospital settings.
• Negri News Magazine Quarterly magazine distributed in both print (35,000 copies) and electronic formats, providing information on research results, institute activities, and health policy.
• Monthly Newsletter Monthly online newsletter reporting the institute's position on current issues, updates on institute initiatives, and recent scientific discoveries.
• Clinical Research Center Aldo e Cele Daccò Clinical research center for rare diseases located in Ranica (Bergamo), conducting genetic studies, biochemical diagnostics, and clinical trials.
• Progetto ORIGIN Population genetic study investigating genetic factors influencing COVID-19 susceptibility and severity, involving voluntary participants from Bergamo province municipalities with questionnaire collection and genetic blood analysis.

Quantifiable outcome

• 70% significant response rate to retinoic acid in hormone-sensitive breast cancer patients (preclinical studies)
• +5 more outcomes

Named customers5 records

Segments8 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• ORIGIN Project Municipalities (Albino, Alzano Lombardo, Nembro)coreStrategic or Co-development Partner · 1 October 2020Municipalities providing patronage and local coordination for the ORIGIN genetic study investigating COVID-19 susceptibility in Bergamo province. These municipalities facilitated voluntary participation of residents in the population genetic study, with the Mario Negri institute providing research methodology and genetic analysis.
• University of Insubria - Department of Biotechnology and Life SciencescoreStrategic or Co-development PartnerAcademic collaboration on Parkinson's disease research, specifically investigating the role of peripheral inflammation in exacerbating brain damage induced by alpha-synuclein protein. Published joint research in Neuropathology and Applied Neurobiology journal.
• Open University UKmajorChannel Partner/ Reseller/ DistributorPartnership for PhD program delivery in English language, allowing Mario Negri to offer international doctoral qualifications in pharmacology and biomedical research.
• Regione Lombardia - Open InnovationminorStrategic or Co-development PartnerRegional innovation initiative promoting open innovation in healthcare, with Mario Negri participating as a research partner in the ecosystem.
• Basel DeclarationminorOthersOrganization promoting awareness and implementation of best practices in animal research. Mario Negri adheres to their guidelines for ethical animal research standards.
• Research4LifeminorOthersGlobal partnership providing developing countries access to scientific literature. Mario Negri supports this initiative for expanding research access in underserved regions.
• Comitato Etico Papa Giovanni XXIII di BergamocoreOthersEthics committee that approved the ORIGIN project protocol, ensuring all research activities meet ethical standards for human genetic studies and patient data protection.
• Italian National Health Service (SSN) and Medical-Scientific Oncology SocietiesmajorStrategic or Co-development PartnerCollaborative support for publication of 27 national oncology guidelines officially recognized by the Ministry of Health, providing evidence-based therapeutic recommendations for oncologists nationwide.
• Valtellina SpAminorOthersCorporate partner collaborating with Mario Negri to produce COVID-19 informational materials (vademecum), demonstrating private sector support for public health education.
• Consiglio Nazionale del Notariato (CNN) and Consiglio Nazionale del Lavoro (CNL)minorOthersProfessional associations providing patronage and collaboration for testamentary bequest information, helping individuals properly include the institute in their estate planning.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Institut Pasteur: French non-profit foundation dedicated to biomedical research, including genetics, infectious diseases, and public health. Closely comparable to Mario Negri in mission (non-profit biomedical research for public benefit), scope (basic to clinical research), and reliance on donations and government support.
• The Francis Crick Institute: UK-based biomedical research institute conducting discovery science across cancer, genomics, neuroscience, and rare diseases. Comparable in research breadth, non-academic status, and translation-oriented portfolio spanning fundamental research through clinical applications.
• European Institute of Oncology (IEO): Italian IRCCS focused on oncology research, treatment, and prevention, headquartered in Milan. Directly comparable as an Italian IRCCS with overlapping oncology research mandate and clinical-research-center structure.
• IFOM (FIRC Institute of Molecular Oncology): Italian non-profit molecular oncology research institute in Milan, focused on cancer genetics and molecular mechanisms. Comparable as an Italian non-profit research entity specializing in molecular and genetic oncology research with clinical translation ambitions.
• Salk Institute for Biological Studies: US non-profit basic-research institute covering cancer, neuroscience, immunology, and plant biology. Comparable as an independent, non-university-affiliated non-profit research institute combining fundamental biology with disease-oriented programs.
• The Scripps Research Institute: US non-profit biomedical research organization focused on chemistry, structural biology, immunology, and drug discovery. Comparable as a private non-profit research institute with drug-discovery orientation and translation into clinical applications.
• The Wistar Institute: US non-profit biomedical research institute specializing in cancer, immunology, infectious diseases, and vaccine development. Comparable as an independent non-profit research institute with disease-focused translational programs and reliance on grants and philanthropy.
• Fondazione Telethon: Italian non-profit foundation funding and conducting genetic and rare-disease research, including gene therapy. Comparable as an Italian non-profit research organization focused on rare diseases and genetics, with similar funding model (donations, 5x1000) and translational research mission.

Broad incumbents

• Howard Hughes Medical Institute (HHMI): Large US non-profit biomedical research organization supporting Investigator-led research across hundreds of labs. Comparable in non-profit mission, scientific breadth, and talent-centered operating model, but with significantly greater scale and endowment.
• Max Planck Institute for Molecular Biomedicine: German non-profit basic-research institute within the Max Planck Society, focused on molecular and cellular biology relevant to disease. Comparable as a publicly funded, non-profit basic-research organization translating molecular biology into disease-relevant insights.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MarioNegriIRCCS
• YouTubeyoutube.com/user/IstitutoMarioNegri
• Facebookfacebook.com/pages/Istituto-Mario-Negri/188126417873514?ref=ts&fref=t
• LinkedInit.linkedin.com/company/istituto-mario-negri
• Instagraminstagram.com/istitutomarionegri

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mario Negri Institute